Sunitinib
(Synonyms: 舒尼替尼; SU 11248) 目录号 : GC17651舒尼替尼Sunitinib(SU 11248)是一种具口服活性的多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体(VEGFR2)和血小板衍生生长因子受体(PDGFRβ)的IC50分别为80nM和2nM。
Cas No.:557795-19-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines | 786-O cells |
Preparation Method | Phosphoproteome analysis was performed on lysates of 786-O cells that were untreated or exposed to 2 and 5 μM sunitinib for 2 h. Treatment with 1.0 μM staurosporine was used as a positive control for inhibition of tyrosine kinases. |
Reaction Conditions | 2、5μM; 2h |
Applications | At both sunitinib concentrations, 180 phosphopeptides from 129 proteins showed >1.5-fold changes in more than 2 out of 3 experiments. Of these, 86 phosphopeptides were downregulated and 94 were upregulated. |
Animal experiment [2]: | |
Animal models | Female Balb/c mice |
Preparation Method | Female Balb/c mice were injected intravenously with 4T1-luc or RENCA-luc tumor cells. Drugs (30, 60, or 120 mg/kg/day sunitinib) were given by oral gavage for 7 days. |
Dosage form | 30, 60, 120 mg/kg/day; p.o. |
Applications | Sunitinib fails to inhibit the growth of 4T1 tumours after they have seeded in the lungs of mice, sunitinib can significantly suppress the growth of RENCA tumours. |
References: [1] Van Der Mijn J C, Broxterman H J, Knol J C, et al. Sunitinib activates Axl signaling in renal cell cancer[J]. International journal of cancer, 2016, 138(12): 3002-3010. [2] Welti J C, Powles T, Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis[J]. Angiogenesis, 2012, 15: 623-641. |
Sunitinib (SU 11248) is an orally active multi-target receptor tyrosine kinase inhibitor with IC50 values of 80 nM and 2 nM for vascular endothelial growth factor receptor (VEGFR2) and platelet-derived growth factor receptor (PDGFRβ), respectively[1]. Sunitinib is an ATP-competitive inhibitor that effectively inhibits the phosphorylation of Ire1α by inhibiting autophosphorylation and subsequent RNase activation[2]. Sunitinib is commonly used to treat advanced renal cell carcinoma and gastrointestinal stromal cancer, as well as non-small cell lung cancer[3].
In vitro, treatment of renal cancer cell 786-O with Sunitinib (2, 5 μM) induced changes in the intracellular phosphorylated proteome, with 180 phosphopeptides showing >1.5-fold changes, 86 phosphopeptides downregulated, and 94 phosphopeptides upregulated[4]. Sunitinib (0-5μM) treatment of medulloblastoma VC312 cells for 24h or 48h increased the levels of cleaved caspase-3 and PARP in a dose-dependent manner, induced cell apoptosis, and inhibited STAT3 and AKT activity[5].
In vivo, oral treatment of mice inoculated with 4T1-luc and RENCA-luc tumor cells with Sunitinib (30, 60, 120mg/kg) failed to inhibit the growth of 4T1 tumors after mouse lung implantation, but significantly inhibited the growth of RENCA tumors[6]. Sunitinib (1mg/kg) treatment of diabetic rats for 4 weeks significantly reduced ovarian stromal degeneration, stromal fibrosis, follicular degeneration, and immune expression of NF-kappaB[7].
References:
[1] Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3 Z)-ylidenemethyl]-2, 4-dimethyl-1 H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase[J]. Journal of medicinal chemistry, 2003, 46(7): 1116-1119.
[2] Ali M M U, Bagratuni T, Davenport E L, et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response[J]. The EMBO journal, 2011, 30(5): 894-905.
[3] Gridelli C, Maione P, Del Gaizo F, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer[J]. The oncologist, 2007, 12(2): 191-200.
[4] Van Der Mijn J C, Broxterman H J, Knol J C, et al. Sunitinib activates Axl signaling in renal cell cancer[J]. International journal of cancer, 2016, 138(12): 3002-3010.
[5] Yang F, Jove V, Xin H, et al. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways[J]. Molecular Cancer Research, 2010, 8(1): 35-45.
[6] Welti J C, Powles T, Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis[J]. Angiogenesis, 2012, 15: 623-641.
[7] Erbas O, Pala H G, Pala E E, et al. Therapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model study[J]. Gynecological Endocrinology, 2015, 31(5): 388-391.
舒尼替尼Sunitinib(SU 11248)是一种具口服活性的多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体(VEGFR2)和血小板衍生生长因子受体(PDGFRβ)的IC50分别为80nM和2nM[1]。Sunitinib是一种ATP竞争性抑制剂,通过抑制自身磷酸化和随后的RNase激活,有效抑制Ire1α的磷酸化[2]。Sunitinib通常用于治疗晚期肾细胞癌和胃肠道间质癌,以及非小细胞肺癌等[3]。
在体外,Sunitinib(2、5μM)处理肾癌细胞786-O,诱导了胞内磷酸化蛋白质组变化,180 种磷酸肽显示出>1.5倍的变化,86个磷酸肽下调,94个磷酸肽上调[4]。Sunitinib(0-5μM)处理髓母细胞瘤 VC312 细胞24h或48h,以剂量依赖性方式增加了裂解的caspase-3和PARP水平,诱导了细胞凋亡,抑制了STAT3和AKT活性[5]。
在体内,Sunitinib(30、60、120mg/kg)通过口服治疗接种4T1-luc和RENCA-luc肿瘤细胞的小鼠,无法抑制4T1肿瘤在小鼠肺部植入后的生长,但可以显著抑制RENCA肿瘤的生长[6]。Sunitinib(1mg/kg)治疗糖尿病大鼠4周,显著降低了卵巢的间质变性、间质纤维化、卵泡变性以及NF-kappaB的免疫表达[7]。
Cas No. | 557795-19-4 | SDF | |
别名 | 舒尼替尼; SU 11248 | ||
化学名 | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | ||
Canonical SMILES | CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C | ||
分子式 | C22H27FN4O2 | 分子量 | 398.47 |
溶解度 | ≥ 19.9mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.5096 mL | 12.548 mL | 25.096 mL |
5 mM | 0.5019 mL | 2.5096 mL | 5.0192 mL |
10 mM | 0.251 mL | 1.2548 mL | 2.5096 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。